AbbVie (ABBV) said Friday that the U.S. FDA has approved a supplemental new drug application for its combination regimen of Venclexta (venetoclax) and acalabrutinib to treat previously untreated ...

AbbVie Inc. (NYSE:ABBV) is one of the best value stocks to buy now. On February 20, the US FDA approved the combination of VENCLEXTA (venetoclax) and acalabrutinib as a first-line treatment for adults ...

The FDA is to give AstraZeneca’s cancer drug acalabrutinib a fast review in a rare blood cancer, as the company hopes to shake off disappointing results from a crucial lung cancer trial last week.

(RTTNews) - Genentech, a member of the Roche Holding AG (RHHBY), said on Friday that the U.S. Food and Drug Administration has approved the combination of Venclexta plus acalabrutinib for the ...

First all-oral, fixed-duration combination regimen approved for previously untreated patients with CLL Approval supported by data from the Phase 3 AMPLIFY trial Regimen offers another option for the ...

NHS England is to grant immediate access to AstraZeneca’s cancer drug Calquence (acalabrutinib) for certain patients with chronic lymphocytic leukaemia (CLL) after NICE backed it in first draft ...

AstraZeneca has secured a key regulatory win in its effort to reclaim the lead in the BTK inhibitor market, with the FDA approving its combination of Calquence plus Venclexta as the first all-oral, ...

Acalabrutinib in combination with venetoclax reduced the risk of disease progression or death by 35% compared with investigator’s choice of chemotherapy. The Food and Drug Administration (FDA) has ...

This is the second of five long vowel programmes in our series of videos that explore the sounds of English. This is the second of eight other consonant programmes in our series of videos that explore ...

The safety profile of Venclexta plus acalabrutinib is consistent with the known safety profile of each individual therapy alone. In chronic lymphocytic leukemia or small lymphocytic lymphoma, the most ...